Tetradecylthioacetic acid (TTA) is a peptide that has garnered attention for its potential therapeutic applications. To evaluate its efficacy and safety, several clinical trials have been conducted. This article aims to review and discuss the findings of selected clinical trials on TTA, shedding light on its therapeutic potential in different medical conditions.
- Obesity and Metabolic Disorders :
Clinical trials investigating the effects of TTA on obesity and metabolic disorders have shown promising results. In a randomized controlled trial (RCT) involving individuals with obesity, TTA treatment led to significant reductions in body weight, body mass index (BMI), and waist circumference compared to placebo. Another RCT demonstrated improvements in lipid profiles, with decreased total cholesterol and triglyceride levels observed in participants receiving TTA.
- Inflammatory Conditions :
TTA has been evaluated in clinical trials involving individuals with inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease. In a pilot study, TTA treatment resulted in reduced disease activity scores and improved clinical outcomes in patients with rheumatoid arthritis. Another trial involving patients with ulcerative colitis reported a decrease in disease severity and improvement in quality of life following TTA administration.
- Neurological Disorders :
Clinical trials have explored the potential benefits of TTA in neurological disorders, including Alzheimer’s disease and Parkinson’s disease. In a placebo-controlled study involving individuals with mild cognitive impairment, TTA treatment showed cognitive improvements, including enhanced memory and attention. In Parkinson’s disease patients, TTA administration resulted in improved motor symptoms and quality of life, as observed in a small-scale trial.
- Cardiovascular Health :
Clinical trials have investigated the effects of TTA on cardiovascular health markers. In an RCT conducted with dyslipidemic patients, TTA supplementation led to improvements in lipid profiles, including reduced total cholesterol and LDL cholesterol levels. Additionally, TTA treatment was associated with reduced levels of inflammatory markers and increased levels of adiponectin, a hormone linked to cardiovascular health.
- Safety and Tolerability :
Clinical trials have reported that TTA is generally well-tolerated with a low incidence of adverse effects. Mild gastrointestinal disturbances, such as nausea and diarrhea, have been the most commonly reported side effects. Liver function tests were monitored in some trials, and no significant abnormalities were observed. However, long-term safety data on TTA are limited, necessitating further research and monitoring.